Friday, October 07, 2022 3:38:47 PM
exwannabe,
By all appearances it’s a done deal ex. Manufacturing for approval is all that’s left. FDA is only apparently behind because of “influences” beyond their control and their current set up. They “interfered” with a trial in a statistically meaningful way for undisclosed reasons. I believe this was so that everything could be put in place for approval with manufacturing and unimpeachable data as “the process” took it’s course.
The exceptions rule and manufacturing approvals are clearly in play and I believe FDA guidance updates promised for last December and still not published have been delayed due to pressure not to give NWBO any public support for THEIR use of ECAs before approval.
The $.01/month uptrend was never broken through even on May 10th and now it’s game on. You admitted missing out on a 10x plus potential return from the double bottom that was called on this board. If not invested at prices like we have had recently then you will miss out much more based on what consensus end of year pricing is from skitahoe’s tally of projections. Care to share why you are not invested for or against here?; ). Best wishes.
By all appearances it’s a done deal ex. Manufacturing for approval is all that’s left. FDA is only apparently behind because of “influences” beyond their control and their current set up. They “interfered” with a trial in a statistically meaningful way for undisclosed reasons. I believe this was so that everything could be put in place for approval with manufacturing and unimpeachable data as “the process” took it’s course.
The exceptions rule and manufacturing approvals are clearly in play and I believe FDA guidance updates promised for last December and still not published have been delayed due to pressure not to give NWBO any public support for THEIR use of ECAs before approval.
The $.01/month uptrend was never broken through even on May 10th and now it’s game on. You admitted missing out on a 10x plus potential return from the double bottom that was called on this board. If not invested at prices like we have had recently then you will miss out much more based on what consensus end of year pricing is from skitahoe’s tally of projections. Care to share why you are not invested for or against here?; ). Best wishes.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
